Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1012Lung Neoplasms 769Small Cell Lung Carcinoma 159Breast Neoplasms 73Adenocarcinoma of Lung 68Neoplasms 67Colorectal Neoplasms 50NSCLC 49Melanoma 48Stomach Neoplasms 46Pleural Effusion, Malignant 46Pancreatic Neoplasms 45Brain Neoplasms 42Mesothelioma, Malignant 41Ovarian Neoplasms 32Prostatic Neoplasms 31Neoplasm Metastasis 31Head and Neck Neoplasms 30Mesothelioma 28Esophageal Neoplasms 27Carcinoma, Renal Cell 24Carcinoma 24Urinary Bladder Neoplasms 23Lung Diseases 22Colonic Neoplasms 22Thoracic Neoplasms 19Liver Neoplasms 19Thymoma 18Carcinoma, Hepatocellular 18Pleural Effusion 17

Interventions

toripalimab 1anlotinib 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Non Small Cell Lung Cancer Recurrent × Thoracic × Clear all
NCT05842018 2023-05-03

Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
30 enrolled
Thoracic

Non Small Cell Lung Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡